AzTrials
AzTrials

Small Bowel ObstructionRESBOLAPNCT05842135

REsectability Small Bowel Obstruction LAParoscopic (RESBOLAP) Score. Multicentric Data Registry

An observational study of Small Bowel Obstruction, run by San Salvatore Hospital, AST Pesaro-Urbino at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

AIM OF THE STUDY The aim of the study is to develop a Resectability Laparoscopic Score as a helpful instrument during intraoperative decision-making in the setting of emergency laparoscopic surgery for small bowel obstruction (SBO) by analyzing a multicenter data registry. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Small Bowel Obstruction
What is being tested?
Laparoscopic approach to small bowel obstrcuction
Type of treatment
Surgery or procedure
How many people
171 participants
Where
1 siteItaly
Study dates
15 Dec 2022to 30 Jun 2024
How long will I take part?
1 Week
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: All patients more undergoing emergency laparoscopic surgery for SBO with intraoperative doubts about bowel viability after the resolution of the occlusive mechanism

Who may be able to join

  • All centers that routinely perform emergency laparoscopic surgery for SBO and have imaging systems with technology for the detection of near-infrared/indocyanine green fluorescence
  • All patients more than 18 years old undergoing emergency laparoscopic surgery for SBO with intraoperative doubts about bowel viability after the resolution of the occlusive mechanism

Who cannot join

  • Open surgical procedure for SBO

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Department of General Surgery, San Salvatore Hospital , AST Pesaro-Urbino

    Pesaro, Pesaro-Urbino, 61121

Other trials in Italy

About this study

AIM OF THE STUDY The aim of the study is to develop a Resectability Laparoscopic Score as a helpful instrument during intraoperative decision-making in the setting of emergency laparoscopic surgery for small bowel obstruction (SBO) by analyzing a multicenter data registry.

DESIGN OF THE STUDY This is a multicenter study composed of a first phase of prospective data collection from patients that undergo laparoscopic surgery with a diagnosis of SBO and undergo Indocyanine green (ICG) fluorescence angiography (FA) for doubts about bowel viability after the resolution of the obstructive mechanism; the second phase of retrospective analysis to develop the Resectability Score.

Read more

METHODS The FA should be performed in all patients undergoing laparoscopic surgery for SBO that presents concerns bowel viability after the resolution of the occlusive mechanism, with consequent intraoperative enrolment in the study Registry.

The investigators adopted the modified Bulkley classification of the fluorescent patterns to identify which patients need more FA to assess bowel vitality.

It is expected that most patients for whom the FA will be performed are those with patterns 2 or 3, representing the study's primary object.

All participant centers must adopt the same technique to perform FA with the attempt to homogenize the procedure.

Twenty-five milligrams of ICG powder is suspended in 10 ml of sterile water and administered intravenously through a peripheral vein and in small repeatable boluses of 2 ml in order to evaluate the intestinal microcirculation extemporaneously. The presence and pattern of arterial supply is tested and compared with that of healthy bowel. Proper clearance of the dye was also appraised to verify adequate venous drainage. Following the reversal of the underlying cause of the ischaemic injury, and after generous irrigation with warm saline, the involved bowel segment was further evaluated with FA after 10 min, regardless of the return of visible peristalsis.

Routine postoperative clinical judgment will be considered sufficient to check bowel vitality.

The need for a second-look surgery and delayed resections will be recorded. All centers could participate with a maximum of 3-4 members (co-authorship) Data will be recorded by a simple and brief online Case Report Form (CRF) on which upload also a photo/brief video of the FA, will be filled out by every participating center for each patient.

A link to a Google Form and the necessary documents will be sent to every center after they have accepted to participate in the study.

Read the detailed description

Albeit the role of laparoscopy in the treatment of acute small bowel obstruction (SBO) has grown significantly over the last decade, the inability to obtain an adequate evaluation of compromised bowel segments has been considered as real limitation. This is essentially due to a reduced field of view owing to intestinal distension, the minimized haptic feedback obtained and limited bi-dimensional visualization. As a consequence, the presence of normal visual clues to irreversible vascular insufficiency is much reduced.

Such signs include stable discoloration of the bowel wall, absence of peristaltic movements and apparent mesenteric pulsation. Intestinal perfusion and viability are largely assessed by means of the clinical eye. However, this method lacks objectivity and accuracy, irrespective of a surgeon's experience. Routinely clinical judgment may be appropriate, but the rate of conversion due to concerns regarding bowel viability can be high. Where there are concerns for intestinal ischaemic injury without absolute indications to bowel resection (areas of mural gangrene or bowel necrosis with perforation) intestinal compromise can be appraised by real-time fluorescent analysis of the vascular supply.

Some authors reported their experience on the use of the ICG fluorescent angiography (FA) to assess bowel viability during laparoscopic approach in emergency surgery for SBO, with promising results. Nowadays, an important drawback of qualitative intraoperative assessment of bowel compromise with FA is the interpretation and definition of the boundaries between bowel viability and irreversible ischemia in order to avoid or reduce the rate of delayed bowel necrosis and perforation. An instrument more objective as possible to help surgeons during the intraoperative decision-making is lacking. A resectability score could be resolutive but a large amount of data from a multicentric data registry is needed.

Finally, when the registry will be completed, a logistic regression analysis will be used to identify independent predictive factors of bowel resectability by calculation of odds ratios and its 95% CI based on delayed bowel resection rate too. Significant continuous variables will be transformed into categorical variables using receiver operating characteristic (ROC) curves. The sample size required for the development of the Score was determined according to previous reports. The number of unnecessary bowel resections has been estimated around 46%. Two studies on ICG-fluorescence angiography use during laparoscopic surgery for SBO reported 28.6% of resection rate. The investigators adopted this degree of difference as the maximum error tolerance of 17.4%. Considering a power of 0.9 , a significance level of 0.05 , a 95% CI with its two sides of 0.112 and 0.46, the required sample size will be of 26 subjects that will undergo to bowel resection that must be associated with other 26 subjects with no bowel resection and other 26 will undergo delayed bowel resection, for a total of 78 patients. According to this sample size the score will have a sensitivity of 0.28, a specificity of 0.73, a positive predictive value of 0.22, a negative predictive value of 0.73 and a precision value of 0.39.

The optimal cut-off point with the highest sum of sensitivity and specificity will be chosen for each variable, also the overall predictive value of the Score will be assessed. Finally, a score will be developed by assigning coefficient points to each variable.

Being tested
Laparoscopic approach to small bowel obstrcuction
Keywords
indocyanine green fluorescence, small bowel obstruction, fluorescent angiography, resectability score, laparoscopic emergency surgery

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Laparoscopic approach to small bowel obstrcuctionProcedure or surgery

    Also called indocyanine green fluorescent angiograhy

    Bowel viability assessment by indocyanine green fluorescent angiography during laparoscopic approach to small bowel obstruction

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Development of a resectability laparoscopic score based on data of a multicentric data registry

    Based on these items a resectability laparoscopic score is developed:

    • Length of compromised bowel expressed in centimeters
    • Quality of peritoneal fluid
    • Time to presence of peristalsis after resolution of the obstruction expressed in minutes
    • Time of return to healty bowel coloration after resolution of the obstruction expressed in minutes
    • ICG-fluorescence angiographic patterns
    • Bowel resection rate expressed as event/non event
    • Reintervention rate expressed as event/non event
    • Date of reintervention expressed in days
    • Delayed bowel resection rate expressed as event/non event

    Measured: Event occurred at the time of surgery or after the first surgical interventional without bowel resection

Secondary outcomes (1)
  1. Development of a multicentric data registry of patients underwent laparoscopic approach to small bowel obstruction and ICG fluorescent angiography

    A Data Registry is constructed from multicentric data

    Measured: 12 months eventually extended by further 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 May 2023
  2. Study start15 Dec 2022
  3. Primary completion31 Dec 2023
  4. Study completion30 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case crossover
Time perspective
Other
Enrolment
171 participants (actual)
Target duration
1 Week
IDs, dates and publications
ClinicalTrials.gov ID
NCT05842135
Sponsor's protocol ID
CERP22078
Acronym
RESBOLAP
Status last verified
Apr 2024
First submitted
11 Apr 2023
Last updated
10 Feb 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Small Bowel Obstruction, run by San Salvatore Hospital, AST Pesaro-Urbino at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Development of a resectability laparoscopic score based on data of a multicentric data registry (time frame: Event occurred at the time of surgery or after the first surgical interventional without bowel resection). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in